)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Hua Medicine (2552) investor relations material
Hua Medicine H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary29 Aug, 2025
Executive summary
Net sales for HuaTangNing/dorzagliotin surged 112% year-over-year to RMB 217.4 million in H1 2025, with sales volume up 108% to 1.764 million packs, driven by full self-commercialization and expanded hospital coverage.
Achieved first half-year profit of RMB 1.18 billion, supported by a one-time release of RMB 1.24 billion in deferred income after the Bayer agreement termination.
Gross profit margin improved to 54.2% from 46.5% year-over-year, reflecting increased production scale and efficiency.
Inclusion in China's NRDL and expanded reimbursement coverage accelerated patient adoption, especially in Tier 2 and Tier 3 hospitals.
Advanced clinical and real-world studies, expanded patent portfolio, and filed dorzagliatin registration in Hong Kong, supporting global ambitions.
Financial highlights
Gross profit rose 147% year-over-year to RMB 117.8 million, with gross margin at 54.2% and selling expenses reduced as a percentage of sales.
Administrative expenses dropped to RMB 53.1 million, and R&D expenses fell to RMB 65.8 million for H1 2025.
Net profit reached RMB 1.18 billion, mainly due to the one-time deferred income release.
Cash and cash equivalents stood at RMB 1,022.8 million as of June 30, 2025, supporting future R&D and commercialization.
Profit before tax was RMB 1,183.9 million, up 932% year-over-year; total comprehensive income was RMB 1,184.1 million, up 934%.
Outlook and guidance
Confident in achieving or exceeding RMB 1 billion in annual sales by 2027, with 40% year-over-year growth expected.
Focus on disciplined commercial execution, expanding R&D for dorzagliatin and 2nd generation GKA, and pursuing new indications in metabolic disorders.
Registration of dorzagliatin in Hong Kong and expansion into Southeast Asia, Portuguese-speaking countries, and Belt and Road nations underway.
Continued investment in digital platforms and AI to enhance branding and operational efficiency.
R&D spending expected to rise above last year's level, leveraging stable sales growth.
Explain H1 2025 sales expense reduction
Timeline for dorzagliatin-metformin FDC launch?
How does dorzagliatin achieve diabetes remission?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Hua Medicine earnings date
H2 202527 Mar, 2026
Next Hua Medicine earnings date
H2 202527 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Hua Medicine is a China-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of metabolic diseases. The company specializes in drug candidates targeting type 2 diabetes and related conditions, leveraging internal research and clinical development capabilities. Hua Medicine conducts both domestic and international clinical trials and collaborates with academic and industry partners to advance its pipeline. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage